Dr. Hope Anderson
Vascular Biology, Canadian Centre for Agri-Food Research in Health and Medicine
Vice Dean, Graduate Studies
Rady Faculty of Health Sciences, University of Manitoba
Acting Associate Dean
Faculty of Graduate Studies, University of Manitoba
College of Pharmacy & Department of Pharmacology and Therapeutics, University of Manitoba
- Cardioprotective effects of CLA, a dietary polyunsaturated fatty acid that occurs naturally in dairy and meat products from ruminant animals.
- Elucidation of novel signaling mechanisms underlying cardiac hypertrophy. A specific example includes diacylglycerol kinase signaling in the nucleus of heart muscle cells.
- Mechanisms of defective artery function in hypertension, and effects of candidate dietary interventions.
Why is this work important?
In medical practice, emphasis is now routinely placed on dietary modification as a preventative measure to forestall cardiovascular disease. Unfortunately, fully exploiting the preventative value of nutritional intervention is posing a huge challenge given the complex interaction between diet and bodily function. We need more information about specific dietary approaches and how they work. The goal of our research program is to understand how risk factors for cardiovascular disease, especially diabetes, hypertension, and cardiac hypertrophy, promote the development of heart failure. Our ultimate aim is to identify new therapies, from a nutritional perspective, that prevent or slow the onset of heart failure.
What techniques and equipment are used in this laboratory?
- in vivo study of cardiovascular disease: echocardiography, tail-cuff plethysmography
- in vitro study of cardiac hypertrophy: cell culture, confocal microscopy, planimetry, promoter-reporter assays, biochemical assays (immunoblotting, immunoprecipitation, etc)
- in vitro study of arteries: pressure myography
About Hope Anderson
Dr. Hope Anderson is an Associate Professor of Pharmacy and Pharmacology & Therapeutics at the University of Manitoba. She also serves as Vice Dean, Graduate Studies (Rady Faculty of Health Sciences) and Acting Associate Dean (Faculty of Graduate Studies). The goal of her research program is to understand how risk factors for cardiovascular disease, especially hypertension (high blood pressure), cardiac hypertrophy (abnormal growth of the heart), and diabetes promote the development of heart failure. Her ultimate aim is to identify new therapies, perhaps from a nutritional perspective, that prevent or slow the onset of heart failure. To achieve this aim, Dr. Anderson’s laboratory at the St. Boniface Hospital Research Centre uses several models of cardiovascular disease of escalating complexity ranging from cultured heart muscle cells, to isolated hearts and arteries, to hearts and arteries in vivo.
For more information, please contact:
Dr. Hope Anderson
Tel. (204) 235-3587
Fax. (204) 237-4018
Acosta C, Anderson HD, Anderson CM. Astrocyte dysfunction in Alzheimer’s disease. J Neurosci Res. 2017. doi: 10.1002/jnr.24075.
Alrushaid S, Sayre CL, Maayah ZM, Zhao Y, Forrest ML, Senadheera S, Chaboyer K, Anderson HD , El-Kadi A, Davies NM. mechanistically elucidating the in-vitro safety and efficacy of a novel doxorubicin derivative. Drug Deliv Transl Res. 2017. doi: 10.1007/s13346-017-0379-2.
Lee DI, Acosta C, Anderson CM, Anderson HD. Peripheral and cerebral resistance arteries in the spontaneously hypertensive heart failure rat: effects of stilbenoid polyphenols. Molecules. 2017. 22(3). pii: E380. doi: 10.3390/molecules22030380.
Akinwumi BC, Pema R, Lee DI, Acosta C, Yu L, Thomas SM, Nagabhushanam K, Majeed M, Davies NM, Netticadan TN, Anderson HD. Disparate effects of stilbenoid polyphenols on hypertrophic cardiomyocytes in vitro vs. in the spontaneously hypertensive heart failure rat. Molecules. 2017. 22(2). pii: E204. doi: 10.3390/molecules22020204.
Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017. 95:311-327. doi: 10.1139/cjpp-2016-0346.
Hanson MG, Taylor CG, Wu Y, Anderson HD, Zahradka P. Lentil consumption reduces resistance artery remodeling and restores arterial compliance in the spontaneously hypertensive rat. J Nutr Biochem. 2016;37:30-38. doi: 10.1016/j.jnutbio.2016.07.014.
Aloud B, Raj P, O’Hara KA, Shao Z, Yu L, Anderson HD*, Netticadan TN*. Conjugated linoleic acid prevents high glucose-induced contractile dysfunction and hypertrophy in adult rat cardiomyocytes. Nutr Res. 2016 Feb;36(2):134-42. doi: 10.1016/j.nutres.2015.11.012. *co-corresponding authors
Sayre CL, Alrushaid S, Martinez SE, Anderson HD, Davies NM. Pre-clinical pharmacokinetic and pharmacodynamic characterization of selected chiral flavonoids: pinocembrin and pinostrobin. J Pharm Pharm Sci. 2015;18(4):368-95.
Remsberg CM, Martinez SE, Akinwumi B, Anderson HD, Takemato JK, Sayre CL, Davies NM. Pre-Clinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs. Phytother Res. 2015; 29:1168-1179. DOI: 10.1002/ptr.5363.
Zhang H, Shao Z, Alibin CP, Acosta C, Anderson HD. Liganded Peroxisome Proliferator-Activated Receptors (PPARs) preserve nuclear histone deacetylase 5 levels in endothelin-treated rat cardiac myocytes. PLOS ONE. 2014; 9(12): e115258. doi:10.1371/journal.pone.0115258.
Lu Y, Akinwumi BC, Shao Z, Anderson HD. Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. J Cardiovasc Pharmacol. 2014; 64:420–430. DOI: 10.1097/FJC.0000000000000134.
LeMaistre Stobart JL, Lu L, Anderson HD, Mori H, Anderson CM. Astrocyte-induced cortical vasodilation is mediated by D-serine and endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 2013; 110:3149-3154. DOI: 10.1073/pnas.1215929110.
Thandapilly SJ, Louis XL, Behbahani J, Movahed A, Yu A, Fandrich R, Zhang S, Kardami E, Anderson HD, Netticadan T. Reduced hemodynamic load aids low dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens Res. 2013; 36:866-872. DOI: 10.1038/hr.2013.55.
Cleverley K, Du X, Premecz S, Le K, Zeglinski M, Nicholson T, Goh CY, Lu Y, Anderson HD, Moghadasian MH, Jassal DS. The effects of fish oil consumption on cardiovascular remodeling in ApoE deficient mice. Can J Physiol Pharmacol. 2013. 91:960-965. DOI: 10.1139/cjpp-2013-0077.
Thandapilly SJ, LeMaistre JL, Louis XL, Anderson CM, Netticadan T, Anderson HD. Vascular and cardiac effects of grape powder in the spontaneously hypertensive rat. Am J Hypertens. 2012; 25:1070-1076. DOI: 10.1038/ajh.2012.98.
Wang Y, Jacome-Sosa MM, Ruth MR, Lu Y, Shen J, Reaney MJ, Scott SL, Dugan ME, Anderson HD, Field CJ, Proctor SD, Vine DF. The intestinal bioavailability of vaccenic acid and activation of peroxisome proliferator-activated receptor-α and -γ in a rodent model of dyslipidemia and the metabolic syndrome. Mol Nutr Food Res. 2012; 56:1234-1246. DOI: 10.1002/mnfr.201100517.
LeMaistre JL, Sanders SA, Stobart MJ, Lu L, Knox JD, Anderson HD and Anderson CM. Coactivation of NMDA receptors by glutamate and D-serine induces dilation of isolated middle cerebral arteries. J Cereb Blood Flow Metab. 2012; 32:537-547. DOI: 10.1038/jcbfm.2011.161.
Huang Y, Zhang H, Shao Z, O’Hara KA, Kopilas MA, Yu L, Netticadan T, Anderson HD. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta. Cardiovascular Research. 2011; 90:267-275. DOI: 10.1093/cvr/cvq401.
Thandapilly SJ, Louis XL, Yang T, Stringer DM, Yu L, Zhang S, Wigle J, Kardami E, Zahradka P, Taylor C, Anderson HD, Netticadan T. Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. Eur J Pharmacol. 2011; 668:217-224. DOI: 10.1016/j.ejphar.2011.06.042.
Behbahani J, Thandapilly SJ, Louis XL, Huang Y, Shao Z, Kopilas MA, Wojciechowski P, Netticadan T, Anderson HD. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens. 2010; 23:1273-1278. DOI: 10.1038/ajh.2010.161.
Hunt WT, Kamboj A, Anderson HD, Anderson CM. Protection of cortical neurons from excitotoxcity by conjugated linoleic acid. J Neurochem. 2010;115:123-130. DOI: 10.1111/j.1471-4159.2010.06908.x.
Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, Kopilas MA, Anderson HD, Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010; 23:192-196. DOI: 10.1038/ajh.2009.228.
Alibin CP, Kopilas MA, Anderson HDI. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid: role of peroxisome proliferator-activated receptors α and γ. J Biol Chem. 2008; 283:10707-10715. DOI: 10.1074/jbc.M800035200.
Kopilas MA, Dang LN, Anderson HDI. Effect of dietary trivalent chromium on resistance artery function and nitric oxide signaling in the sucrose-fed spontaneously hypertensive rat. J Vasc Res. 2007; 44:110-118. DOI: 10.1159/000098483.
Aminot-Gilchrist DV, Anderson HDI. Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. Am J Clin Nutr. 2004; 79:1159S-1163S.
Anderson HDI, Wang F, Gardner DG. Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene. J Biol Chem. DOI: 10.1074/jbc.M309227200. 2004; 279:9287-9297.
Anderson HDI, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem. 2004; 279:963-969. DOI: 10.1074/jbc.M309552200.
Chen S, Cao L, Intengan HD, Cui J, Humphreys M, Gardner DG. Osmoregulation of eNOS gene expression in inner medullary collecting duct cells. Role in activation of the type A natriuretic peptide receptor. J Biol Chem. 2002; 277:32498-32504. DOI: 10.1074/jbc.M202321200.
Liang F, Kovacic-Milivojevic B, Chen S, Cui J, Roediger F, Intengan HD, Gardner DG. Signaling mechanisms underlying strain-dependent brain natriuretic peptide gene transcription. Can J Physiol Pharmacol. 2001; 79:640-645. DOI: 10.1139/cjpp-79-8-640.
Intengan HD, Schiffrin EL. Vascular remodeling in hypertension. Roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001; 38:581-587.
Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000; 36:312-318.
Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension. 2000; 35:1221-1225.
Intengan HD, Schiffrin EL. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneous hypertensive rats on endothelial function of resistance arteries. J. Cardiovasc. Pharmacol. 2000; 35:763-768. DOI: 10.1097/00005344-200005000-00013.
Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT1 receptor antagonist losartan in essential hypertension. 2000; J Renin-Angio-Aldo S. 1:40-45.
Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the receptor antagonist losartan. Circulation. 2000; 101:1653-1659.
Diep QN, Intengan HD, Schiffrin EL. Endothelin-1 attenuates omega-3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension. 2000; 35:287-291.
Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats. Effects of AT1-angiotensin receptor antagonism and angiotensin converting enzyme inhibition. Circulation. 1999; 100:2267-2275.
Intengan HD, Park JB, Schiffrin EL. Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: role of endothelin. Hypertension. 1999; 34:907-913.
Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension. 1999; 33:569-574.
Intengan HD, Schiffrin EL. Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: Role of endothelin-1. J. Hypertens. 1998; 16:1907-1912. DOI: 10.1097/00004872-199816121-00009.
Intengan HD, He G, Schiffrin EL. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1998; 32:770-777.
Intengan HD, Schiffrin EL. Role of endothelium in modulation of structural changes of small arteries in hypertension: Effects of therapeutic intervention. J. Hypertens. 1998; 16:S97-S101.
Schiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. 1997; 12:354-367.
Intengan HD, Smyth DD. Renal a2a-adrenoceptor subtype function: Wistar as compared to spontaneously hypertensive rats. Br. J. Pharmacol. 1997; 121:861-866. DOI: 10.1038/sj.bjp.0701198.
Intengan HD, Smyth DD. a2a-adrenoceptor subtype stimulation by guanfacine increases osmolar clearance. J. Pharmacol. Exp. Ther. 1997; 281:48-53.
Intengan HD, Smyth DD. Clonidine increases osmolar clearance and free water clearance via activation of two distinct a2-adrenoceptor sites. Br. J. Pharmacol. 1996; 119:663-670.
Belkhiri A, Intengan HD, Klassen GR. A tandem array of 5S ribosomal RNA genes in Pythium irregulare. Gene. 1997; 186:155-159. DOI: 10.1016/S0378-1119(96)00662-2.
Leslie F. Buggey Professorship in Pharmacy, 2015.
Science Editors’ Choice (vol 339, issue 6122, 02/22/13): LeMaistre Stobart JL, Lu L, Anderson HD, Mori H, Anderson CM. Proc Natl Acad Sci USA. Proc Natl Acad Sci USA. 2013; 110:3149-3154. 2013.
Merit Award for any Combination of Teaching, Service, and/or Research, Scholarly Work & Other Creative Activities, University of Manitoba (2010). 2011.
Best of AHA Subspecialty Conferences Distinction for our abstract entitled, “PPARγ-Dependent Upregulation of Diacylglycerol Kinase Zeta in Cardiac Myocytes Requires Sp1.” 2010.
Canadian Hypertension Society New Investigator Award. 2009.
Canadian Institutes of Health Research New Investigator Award. 2005.
Heart and Stroke Foundation of Canada New Investigator Award. (declined). 2005.
Medical Research Council of Canada/Canadian Institutes of Health Research Centennial/Senior Fellowship.
Phase 1: post-doctoral fellowship. 2000.
Phase 2: salary and research support. 2003.
Heart and Stroke Foundation of Canada Post-doctoral Research Fellowship. 1999.
Bio-Mega/Boehringer Ingelheim Research Presentation Award. 1999.
Medical Research Council of Canada Post-doctoral Research Fellowship. 1998.
Medical Research Council of Canada/Canadian Hypertension Society Post-doctoral Research Fellowship. 1996.
Manitoba Health Research Council Studentship. 1996.
Medical Research Council of Canada/Pharmaceutical Manufacturers Association of Canada/ Canadian Hypertension Society/Pfizer Pharmaceuticals Studentship. 1996.
Manitoba Chapter of Sigma Xi, The Scientific Research Society Graduate Student Award. 1996.
Medical Research Council of Canada/Pharmaceutical Manufacturers Association of Canada/Canadian Hypertension Society/Pfizer Pharmaceuticals Studentship. 1995.
Manitoba Medical Services Foundation Research Award. 1995.
Clive Greenway Research Award. 1995.
Canadian Hypertension Society/Hoffmann LaRoche Trainee Award. 1995.
University of Manitoba Graduate Fellowship. 1994.
Department of Pharmacology and Therapeutics, University of Manitoba Studentship. 1992.
Dr. Anderson’s laboratory would like to gratefully acknowledge the following funding agencies and foundations:
- Agri-Food Research and Development Initiative
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada (Manitoba Foundation)
- Manitoba Health Research Council
- Dairy Farmers of Canada
- University of Manitoba Research Grants Program
- Natural Sciences and Engineering Research Council of Canada
- Canada Foundation for Innovation and Partners
- Dr. Paul H.T. Thorlakson Foundation Fund
- Manitoba Medical Services Foundation